Ubiquitin-independent degradation of proteins by the proteasome

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1786, Issue 2, 2008, Pages 153-177

  Jariel Encontre, Isabelle ^a   Bossis, Guillaume ^a   Piechaczyk, Marc ^a  

^a CNRS   (France)

Author keywords

Oncogene; Proteasome; Tumor suppressor; Ubiquitin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 3; INITIATION FACTOR 4F; ONCOPROTEIN; PROTEASOME; PROTEIN C FOS; PROTEIN MDM2; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RETINOBLASTOMA PROTEIN; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR FRA 1; UBIQUITIN; Y BOX BINDING PROTEIN 1;

HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; UBIQUITINATION;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, BIOLOGICAL; ORNITHINE DECARBOXYLASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITINATION;

EID: 56249108370     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2008.05.004     Document Type: Review

References (243)

1. Coux O., Tanaka K., and Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65 (1996) 801-847
2. Rechsteiner M., and Hill C.P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol. 15 (2005) 27-33
3. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
4. Dicato M., Boccadoro M., Cavenagh J., Ha J.L., rousseau, Ludwig H., San Miguel J., and Sonneveld P. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology 70 (2006) 474-482
5. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 21 (2007) 30-36
6. Richardson P.G., Hideshima T., Mitsiades C., and Anderson K.C. The emerging role of novel therapies for the treatment of relapsed myeloma. J. Natl. Compr. Canc. Netw. 5 (2007) 149-162
7. Farras R., Bossis G., Andermarcher E., Jariel-Encontre I., and Piechaczyk M. Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?. Crit. Rev. Oncol. Hematol. 54 (2005) 31-51
8. Glickman M.H., and Raveh D. Proteasome plasticity. FEBS Lett. 579 (2005) 3214-3223
9. Boutet S., and Rando T.A. Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors. Cell 130 (2007) 349-362
10. Forster A., and Hill C.P. Proteasome degradation: enter the substrate. Trends Cell Biol. 13 (2003) 550-553
11. Hoyt M.A., and Coffino P. Ubiquitin-free routes into the proteasome. Cell. Mol. Life Sci. 61 (2004) 1596-1600
12. Orlowski M., and Wilk S. Ubiquitin-independent proteolytic functions of the proteasome. Arch. Biochem. Biophys. 415 (2003) 1-5
13. Verma R., and Deshaies R.J. A proteasome howdunit: the case of the missing signal. Cell 101 (2000) 341-344
14. Mukhopadhyay D., and Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315 (2007) 201-205
15. Collins G.A., and Tansey W.P. The proteasome: a utility tool for transcription?. Curr. Opin. Genet. Dev. 16 (2006) 197-202
16. Huang T.T., and D'Andrea A.D. Regulation of DNA repair by ubiquitylation. Nat. Rev. Mol. Cell Biol. 7 (2006) 323-334
17. Reed S.H., and Gillette T.G. Nucleotide excision repair and the ubiquitin proteasome pathway-do all roads lead to Rome?. DNA Repair 6 (2007) 149-156
18. Borissenko L., and Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 107 (2007) 687-717
19. Heink S., Ludwig D., Kloetzel P.M., and Kruger E. IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9241-9246
20. Rivett A.J., and Hearn A.R. Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr. Protein Pept. Sci. 5 (2004) 153-161
21. Tanahashi N., Murakami Y., Minami Y., Shimbara N., Hendil K.B., and Tanaka K. Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. J. Biol. Chem. 275 (2000) 14336-14345
22. Asher G., Bercovich Z., Tsvetkov P., Shaul Y., and Kahana C. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol. Cell 17 (2005) 645-655
23. Baugh J.M., and Pilipenko E.V. 20S proteasome differentially alters translation of different mRNAs via the cleavage of eIF4F and eIF3. Mol. Cell 16 (2004) 575-586
24. Moorthy A.K., Savinova O.V., Ho J.Q., Wang V.Y., Vu D., and Ghosh G. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner. Embo. J. 25 (2006) 1945-1956
25. Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R., Allday M.J., and Xiao Z.X. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 20 (2005) 699-708
26. Liu C.W., Li X., Thompson D., Wooding K., Chang T.L., Tang Z., Yu H., Thomas P.J., and DeMartino G.N. ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol. Cell 24 (2006) 39-50
27. Treier M., Staszewski L.M., and Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78 (1994) 787-798
28. Hoffmann E., Thiefes A., Buhrow D., Dittrich-Breiholz O., Schneider H., Resch K., and Kracht M. MEK1-dependent delayed expression of Fos-related antigen-1 counteracts c-Fos and p65 NF-kappaB-mediated interleukin-8 transcription in response to cytokines or growth factors. J. Biol. Chem. 280 (2005) 9706-9718
29. Cadwell K., and Coscoy L. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 309 (2005) 127-130
30. Wang X., Herr R.A., Chua W.J., Lybarger L., Wiertz E.J., and Hansen T.H. Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3. J. Cell Biol. 177 (2007) 613-624
31. Tait S.W., de Vries E., Maas C., Keller A.M., D'Santos C.S., and Borst J. Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment. J. Cell Biol. 179 (2007) 1453-1466
32. Polevoda B., and Sherman F. Nalpha -terminal acetylation of eukaryotic proteins. J. Biol. Chem. 275 (2000) 36479-36482
33. Polevoda B., and Sherman F. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J. Mol. Biol. 325 (2003) 595-622
34. Boutet S.C., Disatnik M.H., Chan L.S., Iori K., and Rando T.A. Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors. Cell 130 (2007) 349-362
35. Baboshina O.V., and Haas A.L. Novel multiubiquitin chain linkages catalyzed by the conjugating enzymes E2EPF and RAD6 are recognized by 26 S proteasome subunit 5. J. Biol. Chem. 271 (1996) 2823-2831
36. Hofmann R.M., and Pickart C.M. In vitro assembly and recognition of Lys-63 polyubiquitin chains. J. Biol. Chem. 276 (2001) 27936-27943
37. Kim H.T., Kim K.P., Lledias F., Kisselev A.F., Scaglione K.M., Skowyra D., Gygi S.P., and Goldberg A.L. Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J. Biol. Chem. 282 (2007) 17375-17386
38. Kirkpatrick D.S., Hathaway N.A., Hanna J., Elsasser S., Rush J., Finley D., King R.W., and Gygi S.P. Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat. Cell Biol. 8 (2006) 700-710
39. Deveraux Q., Wells R., and Rechsteiner M. Ubiquitin metabolism in ts85 cells, a mouse carcinoma line that contains a thermolabile ubiquitin activating enzyme. J. Biol. Chem. 265 (1990) 6323-6329
40. Kulka R.G., Raboy B., Schuster R., Parag H.A., Diamond G., Ciechanover A., and Marcus M. A Chinese hamster cell cycle mutant arrested at G2 phase has a temperature-sensitive ubiquitin-activating enzyme, E1. J. Biol. Chem. 263 (1988) 15726-15731
41. Salvat C., Acquaviva C., Scheffner M., Robbins I., Piechaczyk M., and Jariel-Encontre I. Molecular characterization of the thermosensitive E1 ubiquitin-activating enzyme cell mutant A31N-ts20. Requirements upon different levels of E1 for the ubiquitination/degradation of the various protein substrates in vivo. Eur. J. Biochem. 267 (2000) 3712-3722
42. Chiu Y.H., Sun Q., and Chen Z.J. E1-L2 activates both ubiquitin and FAT10. Mol. Cell 27 (2007) 1014-1023
43. Jin J., Li X., Gygi S.P., and Harper J.W. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 447 (2007) 1135-1138
44. Pelzer C., Kassner I., Matentzoglu K., Singh R.K., Wollscheid H.P., Scheffner M., Schmidtke G., and Groettrup M. UBE1L2, a novel E1 enzyme specific for ubiquitin. J. Biol. Chem. 282 (2007) 23010-23014
45. Gaczynska M., and Osmulski P.A. Small-molecule inhibitors of proteasome activity. Methods Mol. Biol. 301 (2005) 3-22
46. Szymanska G., Leszyk J.D., and O'Connor C.M. Carboxyl methylation of deamidated calmodulin increases its stability in Xenopus oocyte cytoplasm. Implications for protein repair. J. Biol. Chem. 273 (1998) 28516-28523
47. Tarcsa E., Szymanska G., Lecker S., O'Connor C.M., and Goldberg A.L. Ca2+-free calmodulin and calmodulin damaged by in vitro aging are selectively degraded by 26 S proteasomes without ubiquitination. J. Biol. Chem. 275 (2000) 20295-20301
48. Braun B.C., Glickman M., Kraft R., Dahlmann B., Kloetzel P.M., Finley D., and Schmidt M. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat. Cell Biol. 1 (1999) 221-226
49. Liu C.W., Corboy M.J., DeMartino G.N., and Thomas P.J. Endoproteolytic activity of the proteasome. Science 299 (2003) 408-411
50. Strickland E., Hakala K., Thomas P.J., and DeMartino G.N. Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. J. Biol. Chem. 275 (2000) 5565-5572
51. Dunlop R.A., Rodgers K.J., and Dean R.T. Recent developments in the intracellular degradation of oxidized proteins. Free Radic. Biol. Med. 33 (2002) 894-906
52. Carrard G., Bulteau A.L., Petropoulos I., and Friguet B. Impairment of proteasome structure and function in aging. Int. J. Biochem. Cell. Biol. 34 (2002) 1461-1474
53. Szweda P.A., Friguet B., and Szweda L.I. Proteolysis, free radicals, and aging. Free Radic. Biol. Med. 33 (2002) 29-36
54. Bader N., and Grune T. Protein oxidation and proteolysis. Biol. Chem. 387 (2006) 1351-1355
55. Jung T., Bader N., and Grune T. Oxidized proteins: intracellular distribution and recognition by the proteasome. Arch. Biochem. Biophys. 462 (2007) 231-237
56. Grune T., Reinheckel T., Joshi M., and Davies K.J. Proteolysis in cultured liver epithelial cells during oxidative stress. Role of the multicatalytic proteinase complex, proteasome. J. Biol. Chem. 270 (1995) 2344-2351
57. Grune T., Reinheckel T., and Davies K.J. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J. Biol. Chem. 271 (1996) 15504-15509
58. Grune T., Reinheckel T., and Davies K.J. Degradation of oxidized proteins in mammalian cells. Faseb J. 11 (1997) 526-534
59. Shringarpure R., Grune T., Mehlhase J., and Davies K.J. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 278 (2003) 311-318
60. Yang Y., Fruh K., Ahn K., and Peterson P.A. In vivo assembly of the proteasomal complexes, implications for antigen processing. J. Biol. Chem. 270 (1995) 27687-27694
61. Brooks P., Fuertes G., Murray R.Z., Bose S., Knecht E., Rechsteiner M.C., Hendil K.B., Tanaka K., Dyson J., and Rivett J. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J. 346 (2000) 155-161
62. Shang F., and Taylor A. Oxidative stress and recovery from oxidative stress are associated with altered ubiquitin conjugating and proteolytic activities in bovine lens epithelial cells. Biochem. J. 307 (1995) 297-303
63. Jahngen-Hodge J., Obin M.S., Gong X., Shang F., Nowell Jr. T.R., Gong J., Abasi H., Blumberg J., and Taylor A. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J. Biol. Chem. 272 (1997) 28218-28226
64. Lasch P., Petras T., Ullrich O., Backmann J., Naumann D., and Grune T. Hydrogen peroxide-induced structural alterations of RNAse A. J. Biol. Chem. 276 (2001) 9492-9502
65. Pacifici R.E., Kono Y., and Davies K.J. Hydrophobicity as the signal for selective degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase complex, proteasome. J. Biol. Chem. 268 (1993) 15405-15411
66. Giulivi C., Pacifici R.E., and Davies K.J. Exposure of hydrophobic moieties promotes the selective degradation of hydrogen peroxide-modified hemoglobin by the multicatalytic proteinase complex, proteasome. Arch. Biochem. Biophys. 311 (1994) 329-341
67. Sacksteder C.A., Whittier J.E., Xiong Y., Li J., Galeva N.A., Jacoby M.E., Purvine S.O., Williams T.D., Rechsteiner M.C., Bigelow D.J., and Squier T.C. Tertiary structural rearrangements upon oxidation of Methionine145 in calmodulin promotes targeted proteasomal degradation. Biophys. J. 91 (2006) 1480-1493
68. Ferrington D.A., Sun H., Murray K.K., Costa J., Williams T.D., Bigelow D.J., and Squier T.C. Selective degradation of oxidized calmodulin by the 20 S proteasome. J. Biol. Chem. 276 (2001) 937-943
69. Whittier J.E., Xiong Y., Rechsteiner M.C., and Squier T.C. Hsp90 enhances degradation of oxidized calmodulin by the 20 S proteasome. J. Biol. Chem. 279 (2004) 46135-46142
70. Kisselev A.F., Kaganovich D., and Goldberg A.L. Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings. J. Biol. Chem. 277 (2002) 22260-22270
71. Orlowski M. Selective activation of the 20 S proteasome (multicatalytic proteinase complex) by histone h3. Biochemistry 40 (2001) 15318-15326
72. Kisselev A.F., Akopian T.N., Woo K.M., and Goldberg A.L. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274 (1999) 3363-3371
73. Gerner E.W., and Meyskens Jr. F.L. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4 (2004) 781-792
74. Pegg A.E. Regulation of ornithine decarboxylase. J. Biol. Chem. 281 (2006) 14529-14532
75. Coffino P. Regulation of cellular polyamines by antizyme. Nat. Rev. Mol. Cell Biol. 2 (2001) 188-194
76. Kahana C., Asher G., and Shaul Y. Mechanisms of protein degradation: an odyssey with ODC. Cell Cycle 4 (2005) 1461-1464
77. Bercovich Z., Rosenberg-Hasson Y., Ciechanover A., and Kahana C. Degradation of ornithine decarboxylase in reticulocyte lysate is ATP-dependent but ubiquitin-independent. J. Biol. Chem. 264 (1989) 15949-15952
78. Glass J.R., and Gerner E.W. Spermidine mediates degradation of ornithine decarboxylase by a non-lysosomal, ubiquitin-independent mechanism. J. Cell Physiol. 130 (1987) 133-141
79. Murakami Y., Matsufuji S., Kameji T., Hayashi S., Igarashi K., Tamura T., Tanaka K., and Ichihara A. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360 (1992) 597-599
80. Rosenberg-Hasson Y., Bercovich Z., Ciechanover A., and Kahana C. Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent. Eur. J. Biochem. 185 (1989) 469-474
81. Elias S., Bercovich B., Kahana C., Coffino P., Fischer M., Hilt W., Wolf D.H., and Ciechanover A. Degradation of ornithine decarboxylase by the mammalian and yeast 26S proteasome complexes requires all the components of the protease. Eur. J. Biochem. 229 (1995) 276-283
82. Murakami Y., Matsufuji S., Hayashi S.I., Tanahashi N., and Tanaka K. ATP-dependent inactivation and sequestration of ornithine decarboxylase by the 26S proteasome are prerequisites for degradation. Mol. Cell Biol. 19 (1999) 7216-7227
83. Zhang M., Pickart C.M., and Coffino P. Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate. Embo J. 22 (2003) 1488-1496
84. Ghoda L., van Daalen Wetters T., Macrae M., Ascherman D., and Coffino P. Prevention of rapid intracellular degradation of ODC by a carboxyl-terminal truncation. Science 243 (1989) 1493-1495
85. Li X., and Coffino P. Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. Mol. Cell Biol. 13 (1993) 2377-2383
86. Chen H., MacDonald A., and Coffino P. Structural elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase. J. Biol. Chem. 277 (2002) 45957-45961
87. Zhang M., MacDonald A.I., Hoyt M.A., and Coffino P. Proteasomes begin ornithine decarboxylase digestion at the C terminus. J. Biol. Chem. 279 (2004) 20959-20965
88. Breitschopf K., Bengal E., Ziv T., Admon A., and Ciechanover A. A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. Embo J. 17 (1998) 5964-5973
89. Prakash S., Tian L., Ratliff K.S., Lehotzky R.E., and Matouschek A. An unstructured initiation site is required for efficient proteasome-mediated degradation. Nat. Struct. Mol. Biol. 11 (2004) 830-837
90. Almrud J.J., Oliveira M.A., Kern A.D., Grishin N.V., Phillips M.A., and Hackert M.L. Crystal structure of human ornithine decarboxylase at 2.1 A resolution: structural insights to antizyme binding. J. Mol. Biol. 295 (2000) 7-16
91. Kern A.D., Oliveira M.A., Coffino P., and Hackert M.L. Structure of mammalian ornithine decarboxylase at 1.6 A resolution: stereochemical implications of PLP-dependent amino acid decarboxylases. Structure Fold Des. 7 (1999) 567-581
92. Takeuchi J., Chen H., and Coffino P. Proteasome substrate degradation requires association plus extended peptide. Embo J. 26 (2007) 123-131
93. Takeuchi J., Chen H., Hoyt M.A., and Coffino P. Structural elements of the ubiquitin-independent proteasome degron of ornithine decarboxylase. Biochem. J. (2007)
94. Leung-Toung R., Li W., Tam T.F., and Karimian K. Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. 9 (2002) 979-1002
95. Gritli-Linde A., Nilsson J., Bohlooly Y.M., Heby O., and Linde A. Nuclear translocation of antizyme and expression of ornithine decarboxylase and antizyme are developmentally regulated. Dev. Dyn. 220 (2001) 259-275
96. Murai N., Murakami Y., and Matsufuji S. Identification of nuclear export signals in antizyme-1. J. Biol. Chem. 278 (2003) 44791-44798
97. Gruendler C., Lin Y., Farley J., and Wang T. Proteasomal degradation of Smad1 induced by bone morphogenetic proteins. J. Biol. Chem. 276 (2001) 46533-46543
98. Lin Y., Martin J., Gruendler C., Farley J., Meng X., Li B.Y., Lechleider R., Huff C., Kim R.H., Grasser W.A., Paralkar V., and Wang T. A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biol. 3 (2002) 15
99. Newman R.M., Mobascher A., Mangold U., Koike C., Diah S., Schmidt M., Finley D., and Zetter B.R. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J. Biol. Chem. 279 (2004) 41504-41511
100. Lim S.K., and Gopalan G. Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A. Oncogene 26 (2007) 6593-6603
101. Lim S.K., and Gopalan G. Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem J. 403 (2007) 119-127
102. Murakami Y., Ichiba T., Matsufuji S., and Hayashi S. Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase. J. Biol. Chem. 271 (1996) 3340-3342
103. Gandre S., Bercovich Z., and Kahana C. Ornithine decarboxylase-antizyme is rapidly degraded through a mechanism that requires functional ubiquitin-dependent proteolytic activity. Eur. J. Biochem. 269 (2002) 1316-1322
104. Bercovich Z., and Kahana C. Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme. J. Biol. Chem. 279 (2004) 54097-54102
105. Dyson H.J., and Wright P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6 (2005) 197-208
106. Asher G., Lotem J., Sachs L., Kahana C., and Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13125-13130
107. Asher G., Tsvetkov P., Kahana C., and Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 19 (2005) 316-321
108. Blagosklonny M.V., Wu G.S., Omura S., and el-Deiry W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 227 (1996) 564-569
109. Cayrol C., and Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 17 (1998) 2437-2444
110. Sheaff R.J., Singer J.D., Swanger J., Smitherman M., Roberts J.M., and Clurman B.E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell 5 (2000) 403-410
111. Touitou R., Richardson J., Bose S., Nakanishi M., Rivett J., and Allday M.J. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. Embo J. 20 (2001) 2367-2375
112. Kim G.Y., Mercer S.E., Ewton D.Z., Yan Z., Jin K., and Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J. Biol. Chem. 277 (2002) 29792-29802
113. Li Y., Dowbenko D., and Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 277 (2002) 11352-11361
114. Rossig L., Badorff C., Holzmann Y., Zeiher A.M., and Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J. Biol. Chem. 277 (2002) 9684-9689
115. Scott M.T., Ingram A., and Ball K.L. PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein. Embo J. 21 (2002) 6771-6780
116. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252
117. Zhu H., Nie L., and Maki C.G. Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J. Biol. Chem. 280 (2005) 29282-29288
118. Bendjennat M., Boulaire J., Jascur T., Brickner H., Barbier V., Sarasin A., Fotedar A., and Fotedar R. UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell 114 (2003) 599-610
119. Lee H., Zeng S.X., and Lu H. UV Induces p21 rapid turnover independently of ubiquitin and Skp2. J. Biol. Chem. 281 (2006) 26876-26883
120. Lee J.Y., Yu S.J., Park Y.G., Kim J., and Sohn J. Glycogen synthase kinase 3beta phosphorylates p21WAF1/CIP1 for proteasomal degradation after UV irradiation. Mol. Cell Biol. 27 (2007) 3187-3198
121. Bornstein G., Bloom J., Sitry-Shevah D., Nakayama K., Pagano M., and Hershko A. Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase. J. Biol. Chem. 278 (2003) 25752-25757
122. Wang W., Nacusi L., Sheaff R.J., and Liu X. Ubiquitination of p21Cip1/WAF1 by SCFSkp2: substrate requirement and ubiquitination site selection. Biochemistry 44 (2005) 14553-14564
123. Amador V., Ge S., Santamaria P.G., Guardavaccaro D., and Pagano M. APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol. Cell 27 (2007) 462-473
124. Jascur T., Brickner H., Salles-Passador I., Barbier V., El Khissiin A., Smith B., Fotedar R., and Fotedar A. Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol. Cell 17 (2005) 237-249
125. Chen X., Barton L.F., Chi Y., Clurman B.E., and Roberts J.M. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell 26 (2007) 843-852
126. Chen X., Chi Y., Bloecher A., Aebersold R., Clurman B.E., and Roberts J.M. N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1). Mol. Cell 16 (2004) 839-847
127. Li X., Amazit L., Long W., Lonard D.M., Monaco J.J., and O'Malley B.W. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell 26 (2007) 831-842
128. Bloom J., Amador V., Bartolini F., DeMartino G.N., and Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 115 (2003) 71-82
129. Yu Z.K., Gervais J.L., and Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 11324-11329
130. Bao W., Thullberg M., Zhang H., Onischenko A., and Stromblad S. Cell attachment to the extracellular matrix induces proteasomal degradation of p21(CIP1) via Cdc42/Rac1 signaling. Mol. Cell Biol. 22 (2002) 4587-4597
131. Jin Y., Lee H., Zeng S.X., Dai M.S., and Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. Embo J. 22 (2003) 6365-6377
132. Coulombe P., Rodier G., Bonneil E., Thibault P., and Meloche S. N-Terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome. Mol. Cell Biol. 24 (2004) 6140-6150
133. Zhang Z., Wang H., Li M., Agrawal S., Chen X., and Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279 (2004) 16000-16006
134. Kriwacki R.W., Hengst L., Tennant L., Reed S.I., and Wright P.E. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc. Natl.Acad. Sci. U. S. A. 93 (1996) 11504-11509
135. Kriwacki R.W., Wu J., Tennant L., Wright P.E., and Siuzdak G. Probing protein structure using biochemical and biophysical methods. Proteolysis, matrix-assisted laser desorption/ionization mass spectrometry, high-performance liquid chromatography and size-exclusion chromatography of p21Waf1/Cip1/Sdi1. J. Chromatogr. A 777 (1997) 23-30
136. Coleman M.L., Marshall C.J., and Olson M.F. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. Embo J. 22 (2003) 2036-2046
137. I. Jariel-Encontre, M. Piechaczyk, c-Fos, Targeted Protein Data Base, (in press).
138. Jochum W., Passegue E., and Wagner E.F. AP-1 in mouse development and tumorigenesis. Oncogene 20 (2001) 2401-2412
139. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 41 (2005) 2449-2461
140. Chinenov Y., and Kerppola T.K. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20 (2001) 2438-2452
141. J. Basbous, I. Jariel-Encontre, T. Gomard, G. Bossis, M. Piechaczyk, Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer, Biochimie 90 (2008) 296-305.
142. Piechaczyk M., and Blanchard J.M. c-fos proto-oncogene regulation and function. Crit. Rev. Oncol. Hematol. 17 (1994) 93-131
143. Ferrara P., Andermarcher E., Bossis G., Brockly F., Jariel-Encontre I., and Piechaczyk M. The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene 22 (2003) 1461-1474
144. Salvat C., Aquaviva C., Jariel-Encontre I., Ferrara P., Pariat M., Steff A.M., Carillo S., and Piechaczyk M. Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?. Mol. Biol. Rep. 26 (1999) 45-51
145. Acquaviva C., Salvat C., Brockly F., Bossis G., Ferrara P., Piechaczyk M., and Jariel-Encontre I. Cellular and viral Fos proteins are degraded by different proteolytic systems. Oncogene 20 (2001) 7563-7572
146. Acquaviva C., Brockly F., Ferrara P., Bossis G., Salvat C., Jariel-Encontre I., and Piechaczyk M. Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition. Oncogene 20 (2001) 7563-7572
147. Salvat C., Jariel-Encontre I., Acquaviva C., Omura S., and Piechaczyk M. Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts. Oncogene 17 (1998) 327-337
148. Bossis G., Ferrara P., Acquaviva C., Jariel-Encontre I., and Piechaczyk M. c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. Mol. Cell Biol. 23 (2003) 7425-7436
149. Sasaki T., Kojima H., Kishimoto R., Ikeda A., Kunimoto H., and Nakajima K. Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role. Mol. Cell 24 (2006) 63-75
150. Coronella-Wood J., Terrand J., Sun H., and Chen Q.M. c-Fos phosphorylation induced by H2O2 prevents proteasomal degradation of c-Fos in cardiomyocytes. J. Biol. Chem. 279 (2004) 33567-33574
151. Ito Y., Inoue D., Kido S., and Matsumoto T. c-Fos degradation by the ubiquitin-proteasome proteolytic pathway in osteoclast progenitors. Bone 37 (2005) 842-849
152. Roux P., Blanchard J.M., Fernandez A., Lamb N., Jeanteur P., and Piechaczyk M. Nuclear localization of c-Fos, but not v-Fos proteins, is controlled by extracellular signals. Cell 63 (1990) 341-351
153. Hermida-Matsumoto M.L., Chock P.B., Curran T., and Yang D.C. Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes. J. Biol. Chem. 271 (1996) 4930-4936
154. Stancovski I., Gonen H., Orian A., Schwartz A.L., and Ciechanover A. Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Mol. Cell Biol. 15 (1995) 7106-7116
155. Tsurumi C., Ishida N., Tamura T., Kakizuka A., Nishida E., Okumura E., Kishimoto T., Inagaki M., Okazaki K., Sagata N., et al. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol. Cell Biol. 15 (1995) 5682-5687
156. Campbell K.M., Terrell A.R., Laybourn P.J., and Lumb K.J. Intrinsic structural disorder of the C-terminal activation domain from the bZIP transcription factor Fos. Biochemistry 39 (2000) 2708-2713
157. Basbous J., Chalbos D., Hipskind R., Jariel-Encontre I., and Piechaczyk M. Ubiquitin-independent proteasomal degradation of fra-1 is antagonized by erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol. Cell. Biol. 27 (2007) 3936-3950
158. Vial E., and Marshall C.J. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci. 116 (2003) 4957-4963
159. Ulery P.G., and Nestler E.J. Regulation of DeltaFosB transcriptional activity by Ser27 phosphorylation. Eur. J. Neurosci. 25 (2007) 224-230
160. Ulery P.G., Rudenko G., and Nestler E.J. Regulation of DeltaFosB stability by phosphorylation. J. Neurosci. 26 (2006) 5131-5142
161. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
162. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21 (2006) 307-315
163. Le Cam L., Linares L.K., Paul C., Julien E., Lacroix M., Hatchi E., Triboulet R., Bossis G., Shmueli A., Rodriguez M.S., Coux O., and Sardet C. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127 (2006) 775-788
164. Scheffner M., and Whitaker N.J. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin. Cancer Biol. 13 (2003) 59-67
165. Asher G., and Shaul Y. p53 proteasomal degradation: poly-ubiquitination is not the whole story. Cell Cycle 4 (2005) 1015-1018
166. Anwar A., Dehn D., Siegel D., Kepa J.K., Tang L.J., Pietenpol J.A., and Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J. Biol. Chem. 278 (2003) 10368-10373
167. Asher G., Lotem J., Tsvetkov P., Reiss V., Sachs L., and Shaul Y. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15065-15070
168. Asher G., Reuven N., and Shaul Y. 20S proteasomes and protein degradation "by default". Bioessays 28 (2006) 844-849
169. Long 2nd D.J., Gaikwad A., Multani A., Pathak S., Montgomery C.A., Gonzalez F.J., and Jaiswal A.K. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res. 62 (2002) 3030-3036
170. Asher G., Lotem J., Kama R., Sachs L., and Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3099-3104
171. Asher G., Lotem J., Cohen B., Sachs L., and Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1188-1193
172. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92 (2000) 690-698
173. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350
174. Camus S., Menendez S., Cheok C.F., Stevenson L.F., Lain S., and Lane D.P. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene (2007)
175. Classon M., and Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2 (2002) 910-917
176. Stevaux O., and Dyson N.J. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14 (2002) 684-691
177. Knight J.S., Sharma N., and Robertson E.S. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18562-18566
178. Munakata T., Nakamura M., Liang Y., Li K., and Lemon S.M. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18159-18164
179. Kalejta R.F., Bechtel J.T., and Shenk T. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors. Mol. Cell Biol. 23 (2003) 1885-1895
180. Kalejta R.F., and Shenk T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3263-3268
181. Sdek P., Ying H., Zheng H., Margulis A., Tang X., Tian K., and Xiao Z.X. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J. Biol. Chem. 279 (2004) 53317-53322
182. Uchida C., Miwa S., Kitagawa K., Hattori T., Isobe T., Otani S., Oda T., Sugimura H., Kamijo T., Ookawa K., Yasuda H., and Kitagawa M. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. Embo J. 24 (2005) 160-169
183. Bardos J.I., and Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta. 1755 (2005) 107-120
184. Kong X., Alvarez-Castelao B., Lin Z., Castano J.G., and Caro J. Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. J. Biol. Chem. 282 (2007) 15498-15505
185. Kong X., Lin Z., Liang D., Fath D., Sang N., and Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell Biol. 26 (2006) 2019-2028
186. Sanchez-Puig N., Veprintsev D.B., and Fersht A.R. Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol. Cell 17 (2005) 11-21
187. Cho S., Choi Y.J., Kim J.M., Jeong S.T., Kim J.H., Kim S.H., and Ryu S.E. Binding and regulation of HIF-1alpha by a subunit of the proteasome complex, PSMA7. FEBS Lett. 498 (2001) 62-66
188. Stoeltzing O., McCarty M.F., Wey J.S., Fan F., Liu W., Belcheva A., Bucana C.D., Semenza G.L., and Ellis L.M. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 96 (2004) 946-956
189. Zhong H., Semenza G.L., Simons J.W., and De Marzo A.M. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev. 28 (2004) 88-93
190. Rasheed W.K., Johnstone R.W., and Prince H.M. Histone deacetylase inhibitors in cancer therapy. Expert. Opin. Investig. Drugs 16 (2007) 659-678
191. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Chung H.Y., Kim C.W., and Kim K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7 (2001) 437-443
192. Mie Lee Y., Kim S.H., Kim H.S., Jin Son M., Nakajima H., Jeong Kwon H., and Kim K.W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 300 (2003) 241-246
193. Williams R.J., and Trichostatin A. an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin. Investig. Drugs 10 (2001) 1571-1573
194. Yang Q.C., Zeng B.F., Shi Z.M., Dong Y., Jiang Z.M., Huang J., Lv Y.M., Yang C.X., and Liu Y.W. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J. Exp. Clin. Cancer Res. 25 (2006) 593-599
195. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., and Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
196. Zhou J., Schmid T., Frank R., and Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J. Biol. Chem. 279 (2004) 13506-13513
197. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., and Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277 (2002) 29936-29944
198. Katschinski D.M., Le L., Heinrich D., Wagner K.F., Hofer T., Schindler S.G., and Wenger R.H. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J. Biol. Chem. 277 (2002) 9262-9267
199. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., and Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105 (2005) 1768-1776
200. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., and Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18 (2005) 601-607
201. Murphy P.J., Morishima Y., Kovacs J.J., Yao T.P., and Pratt W.B. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem. 280 (2005) 33792-33799
202. Krappmann D., and Scheidereit C. Regulation of NF-kappa B activity by I kappa B alpha and I kappa B beta stability. Immunobiology 198 (1997) 3-13
203. Jariel-Encontre I., Pariat M., Martin F., Carillo S., Salvat C., and Piechaczyk M. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome. J. Biol. Chem. 270 (1995) 11623-11627
204. Pena M.M., Xing Y.Y., Koli S., and Berger F.G. Role of N-terminal residues in the ubiquitin-independent degradation of human thymidylate synthase. Biochem. J. 394 (2006) 355-363
205. Kitchens M.E., Forsthoefel A.M., Rafique Z., Spencer H.T., and Berger F.G. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J. Biol. Chem. 274 (1999) 12544-12547
206. Forsthoelfel A.M., Pena M.M.O., Xing Y.Y., Rafique Z., and G. B.F. Structural determinants of the intracellular degradation of human thymidylate synthase. Biochemistry 43 (2003) 1972-1979
207. Sage C.R., Michelitsch M.D., Stout T.J., Biermann D., Nissen R., Finer-Moore J., and Stroud R.M. D221 in thymidylate synthase controls conformation change, and thereby opening of the imidazolidine. Biochemistry 37 (1998) 13893-13901
208. Almog R., Waddling C.A., Maley F., Maley G.F., and Van Roey P. Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP. Protein Sci. 10 (2001) 988-996
209. McKenna N.J., and O'Malley B.W. Minireview: nuclear receptor coactivators-an update. Endocrinology 143 (2002) 2461-2465
210. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
211. Li X., Lonard D.M., Jung S.Y., Malovannaya A., Feng Q., Qin J., Tsai S.Y., Tsai M.J., and O'Malley B.W. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124 (2006) 381-392
212. Lonard D.M., Nawaz Z., Smith C.L., and O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell 5 (2000) 939-948
213. Shao W., Keeton E.K., McDonnell D.P., and Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11599-11604
214. Yan F., Gao X., Lonard D.M., and Nawaz Z. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol. Endocrinol. 17 (2003) 1315-1331
215. Zhou P. REGgamma: a shortcut to destruction. Cell 124 (2006) 256-257
216. Piwko W., and Jentsch S. Proteasome-mediated protein processing by bidirectional degradation initiated from an internal site. Nat. Struct. Mol. Biol. 13 (2006) 691-697
217. Ying H., Furuya F., Zhao L., Araki O., West B.L., Hanover J.A., Willingham M.C., and Cheng S.Y. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J. Clin. Invest. 116 (2006) 2972-2984
218. Abba M.C., Drake J.A., Hawkins K.A., Hu Y., Sun H., Notcovich C., Gaddis S., Sahin A., Baggerly K., and Aldaz C.M. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res. 6 (2004) R499-513
219. Neumann M., and Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB activity. Faseb. J. 21 (2007) 2642-2654
220. Coux O., and Goldberg A.L. Enzymes catalyzing ubiquitination and proteolytic processing of the p105 precursor of nuclear factor kappaB1. J. Biol. Chem. 273 (1998) 8820-8828
221. Lin L., DeMartino G.N., and Greene W.C. Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. Cell 92 (1998) 819-828
222. Orian A., Schwartz A.L., Israel A., Whiteside S., Kahana C., and Ciechanover A. Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain. Mol. Cell Biol. 19 (1999) 3664-3673
223. Palombella V.J., Rando O.J., Goldberg A.L., and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78 (1994) 773-785
224. Sears C., Olesen J., Rubin D., Finley D., and Maniatis T. NF-kappa B p105 processing via the ubiquitin-proteasome pathway. J. Biol. Chem. 273 (1998) 1409-1419
225. Lin L., DeMartino G.N., and Greene W.C. Cotranslational dimerization of the Rel homology domain of NF-kappaB1 generates p50-p105 heterodimers and is required for effective p50 production. Embo. J. 19 (2000) 4712-4722
226. Fan C.M., and Maniatis T. Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway. Nature 354 (1991) 395-398
227. Rousset R., Desbois C., Bantignies F., and Jalinot P. Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome. Nature 381 (1996) 328-331
228. Croy C.H., Bergqvist S., Huxford T., Ghosh G., and Komives E.A. Biophysical characterization of the free IkappaBalpha ankyrin repeat domain in solution. Protein. Sci. 13 (2004) 1767-1777
229. Dantuma N.P., and Masucci M.G. Stabilization signals: a novel regulatory mechanism in the ubiquitin/proteasome system. FEBS Lett. 529 (2002) 22-26
230. Levitskaya J., Sharipo A., Leonchiks A., Ciechanover A., and Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12616-12621
231. Sharipo A., Imreh M., Leonchiks A., Imreh S., and Masucci M.G. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4 (1998) 939-944
232. Zhang M., and Coffino P. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing. J. Biol. Chem. 279 (2004) 8635-8641
233. Venkatraman P., Wetzel R., Tanaka M., Nukina N., and Goldberg A.L. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell 14 (2004) 95-104
234. Bader A.G., and Vogt P.K. An essential role for protein synthesis in oncogenic cellular transformation. Oncogene 23 (2004) 3145-3150
235. Kuwano M., Uchiumi T., Hayakawa H., Ono M., Wada M., Izumi H., and Kohno K. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci. 94 (2003) 9-14
236. Stenina O.I., Poptic E.J., and DiCorleto P.E. Thrombin activates a Y box-binding protein (DNA-binding protein B) in endothelial cells. J. Clin. Invest. 106 (2000) 579-587
237. Stenina O.I., Shaneyfelt K.M., and DiCorleto P.E. Thrombin induces the release of the Y-box protein dbpB from mRNA: a mechanism of transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7277-7282
238. Sorokin A.V., Selyutina A.A., Skabkin M.A., Guryanov S.G., Nazimov I.V., Richard C., Th'ng J., Yau J., Sorensen P.H., Ovchinnikov L.P., and Evdokimova V. Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. Embo J. 24 (2005) 3602-3612
239. Wolffe A.P. Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. Bioessays 16 (1994) 245-251
240. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., and Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 96 (2007) R11-15 Suppl
241. De Benedetti A., and Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23 (2004) 3189-3199
242. Dong Z., and Zhang J.T. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit. Rev. Oncol. Hematol. 59 (2006) 169-180
243. Scherrer K., and Bey F. The prosomes (multicatalytic proteinases; proteasomes) and their relationship to the untranslated messenger ribonucleoproteins, the cytoskeleton, and cell differentiation. Prog. Nucleic Acid. Res. Mol. Biol. 49 (1994) 1-64